Smithfield Trust Co Sells 408 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Smithfield Trust Co lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 59.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 274 shares of the medical research company’s stock after selling 408 shares during the quarter. Smithfield Trust Co’s holdings in IQVIA were worth $54,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IQV. Jag Capital Management LLC lifted its position in IQVIA by 1.6% in the 4th quarter. Jag Capital Management LLC now owns 12,631 shares of the medical research company’s stock worth $2,482,000 after buying an additional 200 shares during the last quarter. Synergy Investment Management LLC bought a new stake in IQVIA in the 4th quarter worth approximately $92,000. Charles Schwab Investment Management Inc. lifted its position in IQVIA by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company’s stock worth $245,026,000 after buying an additional 44,991 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in IQVIA by 1.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 67,473 shares of the medical research company’s stock worth $13,259,000 after buying an additional 1,273 shares during the last quarter. Finally, Plato Investment Management Ltd lifted its position in IQVIA by 69.0% in the 4th quarter. Plato Investment Management Ltd now owns 6,944 shares of the medical research company’s stock worth $1,370,000 after buying an additional 2,836 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $186.04 on Thursday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business has a fifty day moving average price of $198.24 and a 200-day moving average price of $213.66. The company has a market capitalization of $32.80 billion, a PE ratio of 24.81, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on IQV. Barclays dropped their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Truist Financial reaffirmed a “buy” rating and issued a $263.00 price target (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.